Management of people with intermediate-stage hepatocellular carcinoma
Davide Roccarina, Avik Majumdar, Douglas Thorburn et al.
Research Article — Peer-Reviewed Source
Original research published by Roccarina et al. in Cochrane Database of Systematic Reviews. Redistributed under Open Access — see publisher for license terms. MedTech Research Group provides these references for informational purposes. We do not conduct original research. All studies are the work of their respective authors and institutions.
Currently, there is no evidence from randomised clinical trials that people with intermediate-stage hepatocellular carcinoma would benefit from systemic chemotherapy with sorafenib either alone or when transarterial chemoembolisation was used as a cointervention (very low quality evidence). We need high-quality randomised clinical trials designed to measure differences in clinically important outcomes (e.g. all-cause mortality or health-related quality of life).
Full text is available at the publisher.
Read at Publisher| DOI | 10.1002/14651858.cd011649.pub2 |
| Journal | Cochrane Database of Systematic Reviews |
| Year | 2017 |
| Authors | Davide Roccarina, Avik Majumdar, Douglas Thorburn, Brian R Davidson, Emmanuel Tsochatzis, Kurinchi Selvan Gurusamy |
| License | Open Access — see publisher for license terms |
| Citations | 18 |